Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) EBIT Margin (2018 - 2025)

TransMedics (TMDX) has 8 years of EBIT Margin data on record, last reported at 40.26% in Q4 2025.

  • For Q4 2025, EBIT Margin fell 4737.0% year-over-year to 40.26%; the TTM value through Dec 2025 reached 3.73%, down 476.0%, while the annual FY2025 figure was 3.73%, 476.0% down from the prior year.
  • EBIT Margin reached 40.26% in Q4 2025 per TMDX's latest filing, down from 16.2% in the prior quarter.
  • Across five years, EBIT Margin topped out at 23.24% in Q2 2025 and bottomed at 216.61% in Q3 2021.
  • Average EBIT Margin over 5 years is 33.8%, with a median of 13.31% recorded in 2022.
  • Peak YoY movement for EBIT Margin: tumbled -15160bps in 2021, then soared 19502bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 117.17% in 2021, then soared by 82bps to 21.61% in 2022, then skyrocketed by 115bps to 3.21% in 2023, then soared by 122bps to 7.11% in 2024, then tumbled by -667bps to 40.26% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 40.26% in Q4 2025, 16.2% in Q3 2025, and 23.24% in Q2 2025.